anaptysbio
glaxosmithkline
amend
strategic
collaboration
dostarlimab
royalties
anaptysbio
increase
global
net
sales
first
us
approval
endometrial
cancer
anticipated
additional
royalty
anaptysbio
gsk
global
net
sales
niraparib
starting
january
gsk
pay
cash
payment
anaptysbio
within
days
gsk
obtains
freedom
develop
commercialize
combination
third
party
molecules
dostarlimab
fda
bla
ema
maa
regulatory
filing
approval
cash
milestones
anticipated
anaptysbio
upcoming
months
san
diego
globe
newswire
anaptysbio
nasdaq
anab
biotechnology
company
developing
antibody
product
candidates
focused
emerging
immune
control
mechanisms
applicable
inflammation
indications
today
announced
anaptysbio
glaxosmithkline
gsk
amended
collaboration
agreement
amended
agreement
provides
anaptysbio
increased
royalties
dostarlimab
sales
collaboration
royalty
gsk
cash
payment
gsk
receives
freedom
conduct
combination
development
commercialization
third
party
molecules
pleased
continue
strategic
collaboration
gsk
look
forward
anticipated
first
fda
approval
dostarlimab
said
hamza
suria
chief
executive
officer
anaptysbio
three
antibodies
collaboration
generated
anaptysbio
using
somatic
hypermutation
technology
platform
internal
focus
advancement
anaptysbio
antibody
pipeline
pleased
partner
gsk
advancing
novel
therapies
patients
suffering
originally
signed
tesaro
march
gsk
collaboration
focused
advancing
checkpoint
receptor
antagonist
antibodies
oncology
dostarlimab
antagonist
antibody
currently
development
gsk
multiple
oncological
disorders
including
endometrial
cancer
cell
lung
cancer
ovarian
cancer
colorectal
cancer
mismatch
repair
deficient
solid
tumors
cobolimab
antagonist
antibody
antagonist
antibody
also
development
collaboration
various
solid
tumors
dostarlimab
combined
certain
antibodies
small
molecule
agents
including
cobolimab
first
us
fda
approval
dostarlimab
anticipated
treatment
endometrial
cancer
maa
review
also
underway
indication
second
bla
filing
dostarlimab
treatment
mismatch
repair
deficient
cancers
basis
anticipated
first
half
oral
poly
polymerase
parp
inhibitor
received
us
approval
maintenance
treatment
adult
patients
advanced
epithelial
ovarian
fallopian
tube
primary
peritoneal
cancer
complete
partial
response
chemotherapy
regardless
biomarker
status
development
additional
cancer
indications
terms
amended
agreement
gsk
agreed
increase
royalties
due
anaptysbio
upon
net
sales
dostarlimab
previously
royalties
ranged
royalty
tier
applicable
global
net
sales
billion
amended
royalty
terms
range
anaptysbio
receive
annual
global
net
sales
billion
net
sales
billion
billion
cash
milestone
payments
due
collaboration
agreement
remain
unchanged
anaptysbio
anticipates
receiving
million
cash
milestones
next
months
dostarlimab
obtains
fda
ema
regulatory
approval
first
two
indications
additional
million
sales
milestones
anticipated
anaptysbio
upon
achievement
certain
dostarlimab
annual
sales
revenues
gsk
also
agreed
starting
january
pay
anaptysbio
royalty
gsk
global
net
sales
addition
gsk
agreed
pay
anaptysbio
cash
payment
million
within
days
exchange
anaptysbio
provided
gsk
freedom
conduct
development
commercialization
combination
molecules
anaptysbio
anaptysbio
biotechnology
company
developing
antibody
product
candidates
focused
emerging
immune
control
mechanisms
applicable
inflammation
indications
company
proprietary
pipeline
includes
antibody
imsidolimab
previously
referred
treatment
rare
inflammatory
diseases
including
generalized
pustular
psoriasis
gpp
palmoplantar
pustulosis
ppp
skin
toxicities
ichthyosis
antibody
etokimab
previously
referred
treatment
chronic
rhinosinusitis
nasal
polyps
crswnp
eosinophilic
asthma
agonist
program
treatment
certain
autoimmune
diseases
immune
checkpoint
receptors
insufficiently
activated
btla
modulator
program
broadly
applicable
human
inflammatory
diseases
associated
lymphoid
myeloid
immune
cell
dysregulation
anaptysbio
antibody
pipeline
developed
using
proprietary
somatic
hypermutation
shm
platform
uses
vitro
shm
antibody
discovery
designed
replicate
key
features
human
immune
system
overcome
limitations
competing
antibody
discovery
technologies
anaptysbio
also
developed
multiple
therapeutic
antibodies
collaboration
glaxosmithkline
including
antagonist
antibody
dostarlimab
antagonist
antibody
cobolimab
antagonist
antibody
inflammation
collaboration
squibb
including
checkpoint
agonist
antibody
currently
clinical
development
statements
press
release
contains
statements
within
meaning
safe
harbor
provisions
private
securities
litigation
reform
act
including
limited
royalties
milestone
payments
cash
payments
payable
company
timing
outcome
regulatory
submission
approval
dostarlimab
statements
including
words
plan
continue
expect
ongoing
statements
future
tense
statements
statements
involve
risks
uncertainties
well
assumptions
fully
materialize
prove
incorrect
could
cause
results
differ
materially
expressed
implied
statements
statements
subject
risks
uncertainties
may
cause
company
actual
activities
results
differ
significantly
expressed
statement
including
risks
uncertainties
related
company
ability
advance
product
candidates
obtain
regulatory
approval
ultimately
commercialize
product
candidates
timing
results
preclinical
clinical
trials
company
ability
fund
development
activities
achieve
development
goals
company
ability
protect
intellectual
property
risks
uncertainties
described
heading
risk
factors
documents
company
files
time
time
securities
exchange
commission
statements
speak
date
press
release
company
undertakes
obligation
revise
update
statements
reflect
events
circumstances
date
hereof
contacts
dennis
mulroy
anaptysbio
dmulroy
